KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Gross Margin (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Gross Margin for 4 consecutive years, with 100.0% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gross Margin rose 743.0% year-over-year to 100.0%, compared with a TTM value of 100.0% through Dec 2023, up 1369.0%, and an annual FY2024 reading of 100.0%, changed 0.0% over the prior year.
  • Gross Margin was 100.0% for Q4 2023 at AbCellera Biologics, roughly flat from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 137.5% in Q2 2023 and bottomed at 69.07% in Q1 2023.
  • Average Gross Margin over 4 years is 93.69%, with a median of 92.94% recorded in 2020.
  • Peak annual rise in Gross Margin hit 4874bps in 2023, while the deepest fall reached -1683bps in 2023.
  • Year by year, Gross Margin stood at 98.93% in 2020, then fell by 0bps to 98.69% in 2021, then fell by -6bps to 92.57% in 2022, then grew by 8bps to 100.0% in 2023.
  • Business Quant data shows Gross Margin for ABCL at 100.0% in Q4 2023, 100.0% in Q3 2023, and 137.5% in Q2 2023.